Navigation Links
Gentiva(R) Health Services to Present at the Credit Suisse Healthcare Conference
Date:11/2/2009

ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. (Nasdaq: GTIV), a leading provider of comprehensive home health services, announced today that it plans to present at the Credit Suisse Healthcare Conference in Phoenix, Arizona at 2:00 p.m. to 2:30 p.m. ET (12:00 p.m. to 12:30 p.m. local time), Thursday, November 12, 2009.

The presentations will be available to the public via a live audio web cast, which may be accessed by visiting http://investors.gentiva.com/events.cfm. Visitors to this site will also be able to request advance notifications of this or other upcoming Gentiva events.

Gentiva executives will give attendees an overview of the Company's operations and strategic priorities, and review opportunities for growth as the U.S. home health industry provides more services to an aging population.

About Gentiva Health Services, Inc.

Gentiva Health Services, Inc. is a leading provider of comprehensive home health services, delivering innovative, high quality care to patients across the United States. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; respiratory therapy and home medical equipment; infusion therapy services; and other therapies and services. For more information, visit Gentiva's web site, http://www.gentiva.com, and its investor relations section at http://investors.gentiva.com. GTIV-G

Forward-Looking Statement

Certain statements contained in this news release, including, without limitation, statements containing the words "believes," "anticipates," "intends," "expects," "assumes," "trends" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the Company's current plans, expectations and projections about future events. However, such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the following: economic and business conditions, including the ability to access capital markets; demographic changes; changes in, or failure to comply with, existing governmental regulations; legislative proposals for healthcare reform; changes in Medicare and Medicaid reimbursement levels; effects of competition in the markets in which the Company operates; liability and other claims asserted against the Company; ability to attract and retain qualified personnel; availability and terms of capital; loss of significant contracts or reduction in revenues associated with major payer sources; ability of customers to pay for services; business disruption due to natural disasters or terrorist acts; ability to successfully integrate the operations of acquisitions the Company may make and achieve expected synergies and operational efficiencies within expected time-frames; effect on liquidity of the Company's debt service requirements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company's various filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section contained in the Company's annual report on Form 10-K for the year ended December 28, 2008.

    Financial and Investor Contact:
                  John R. Potapchuk
                  631-501-7035
                  john.potapchuk@gentiva.com
    or            Brandon Ballew
                  770-221-6700
                  brandon.ballew@gentiva.com

    Media Contact:
                  Scott Cianciulli
                  Brainerd Communicators
                  212-986-6667
                  cianciulli@braincomm.com

SOURCE Gentiva Health Services, Inc.


'/>"/>
SOURCE Gentiva Health Services, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):